| Primary |
| Urinary Tract Infection |
28.9% |
| Hypertension |
7.9% |
| Skin Test |
7.9% |
| Type 2 Diabetes Mellitus |
7.9% |
| Diabetes Mellitus |
5.3% |
| Paraesthesia |
5.3% |
| Product Used For Unknown Indication |
5.3% |
| Allergy Test |
2.6% |
| Androgenetic Alopecia |
2.6% |
| Asthma |
2.6% |
| Cholangitis |
2.6% |
| Constipation |
2.6% |
| Cystitis |
2.6% |
| Depression |
2.6% |
| Glioblastoma |
2.6% |
| Gout |
2.6% |
| Overgrowth Bacterial |
2.6% |
| Pyrexia |
2.6% |
| Sjogren's Syndrome |
2.6% |
|
| Cytolytic Hepatitis |
12.5% |
| Convulsion |
6.3% |
| Hypertension |
6.3% |
| Insulinoma |
6.3% |
| Muscular Weakness |
6.3% |
| Poor Quality Sleep |
6.3% |
| Premature Baby |
6.3% |
| Premature Labour |
6.3% |
| Rash Morbilliform |
6.3% |
| Skin Test Positive |
6.3% |
| Syncope |
6.3% |
| Thrombocytopenia |
6.3% |
| Tinnitus |
6.3% |
| Type Iii Immune Complex Mediated Reaction |
6.3% |
| Urosepsis |
6.3% |
|
| Secondary |
| Product Used For Unknown Indication |
21.1% |
| Urinary Tract Infection |
9.7% |
| Drug Use For Unknown Indication |
7.9% |
| Respiratory Tract Infection |
7.0% |
| Arthritis Infective |
6.9% |
| Gastrointestinal Infection |
6.9% |
| Genitourinary Tract Infection |
6.9% |
| Osteomyelitis |
6.9% |
| Skin Infection |
6.9% |
| Diarrhoea |
3.8% |
| Hypertension |
3.6% |
| Hypercholesterolaemia |
2.3% |
| Drug Exposure During Pregnancy |
1.5% |
| B-cell Lymphoma |
1.3% |
| Dental Care |
1.3% |
| Depression |
1.3% |
| Lymphoma |
1.3% |
| Atrial Fibrillation |
1.1% |
| Non-small Cell Lung Cancer |
1.1% |
| Prophylaxis |
1.1% |
|
| Rhabdomyolysis |
22.5% |
| Renal Failure Acute |
11.3% |
| Toxic Epidermal Necrolysis |
7.5% |
| Urinary Tract Infection |
7.5% |
| Convulsion |
5.0% |
| Rash Erythematous |
5.0% |
| Thrombocytopenia |
5.0% |
| Weight Decreased |
5.0% |
| Haematemesis |
3.8% |
| Chest Pain |
2.5% |
| Dermatitis Allergic |
2.5% |
| Drug Interaction |
2.5% |
| Duodenal Ulcer |
2.5% |
| Episcleritis |
2.5% |
| Hallucination |
2.5% |
| Hepatic Function Abnormal |
2.5% |
| Hyponatraemia |
2.5% |
| Macrocytosis |
2.5% |
| Neuropathy |
2.5% |
| Paraesthesia |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
18.7% |
| Drug Use For Unknown Indication |
15.8% |
| Hepatic Neoplasm Malignant |
10.1% |
| Prophylaxis |
8.9% |
| Abdominal Pain Upper |
7.1% |
| Disbacteriosis |
4.6% |
| Rheumatoid Arthritis |
4.5% |
| Nausea |
4.0% |
| Diagnostic Procedure |
3.9% |
| Urinary Tract Infection |
3.5% |
| Infection Prophylaxis |
2.7% |
| Hypertension |
2.6% |
| Haemorrhage Prophylaxis |
2.3% |
| Vomiting |
2.1% |
| Back Pain |
1.8% |
| Bone Marrow Conditioning Regimen |
1.6% |
| Renal Transplant |
1.5% |
| Acute Myeloid Leukaemia |
1.5% |
| Multiple Sclerosis |
1.5% |
| Hiv Infection |
1.3% |
|
| Vomiting |
11.5% |
| Hepatic Encephalopathy |
8.9% |
| Staphylococcal Infection |
8.9% |
| Urinary Tract Infection |
8.9% |
| Glomerulonephritis Membranous |
8.3% |
| Death |
5.7% |
| Rhabdomyolysis |
5.7% |
| Transient Ischaemic Attack |
5.7% |
| Swollen Tongue |
4.7% |
| Tremor |
4.2% |
| Disseminated Intravascular Coagulation |
3.1% |
| Thrombocytopenia |
3.1% |
| Urticaria |
3.1% |
| Alveolitis Allergic |
2.6% |
| Colitis Ischaemic |
2.6% |
| Enterobacter Infection |
2.6% |
| Lower Gastrointestinal Haemorrhage |
2.6% |
| Pyrexia |
2.6% |
| Upper Gastrointestinal Haemorrhage |
2.6% |
| Ureteric Obstruction |
2.6% |
|
| Interacting |
| Drug Use For Unknown Indication |
21.6% |
| Cystitis |
16.2% |
| Urinary Tract Infection |
13.5% |
| Atrial Fibrillation |
8.1% |
| Hepatic Cirrhosis |
5.4% |
| Product Used For Unknown Indication |
5.4% |
| Stem Cell Transplant |
5.4% |
| Viral Infection |
5.4% |
| Epilepsy |
2.7% |
| Gout |
2.7% |
| Hypercholesterolaemia |
2.7% |
| Hyperlipidaemia |
2.7% |
| Hypertension |
2.7% |
| Meningioma |
2.7% |
| Neuropathy Peripheral |
2.7% |
|
| Drug Interaction |
46.7% |
| Convulsion |
6.7% |
| Electrocardiogram Qt Prolonged |
6.7% |
| Muscle Necrosis |
6.7% |
| Prothrombin Time Prolonged |
6.7% |
| Rhabdomyolysis |
6.7% |
| Sinus Bradycardia |
6.7% |
| Urinary Tract Infection |
6.7% |
| Venoocclusive Liver Disease |
6.7% |
|
